NasdaqGM - Nasdaq Real Time Price USD

CRISPR Therapeutics AG (CRSP)

Compare
44.68 -0.19 (-0.42%)
As of 9:32 AM EDT. Market Open.
Loading Chart for CRSP
DELL
  • Previous Close 44.87
  • Open 45.00
  • Bid 44.43 x 400
  • Ask 44.95 x 200
  • Day's Range 44.59 - 45.00
  • 52 Week Range 37.55 - 91.10
  • Volume 24,177
  • Avg. Volume 1,283,712
  • Market Cap (intraday) 3.805B
  • Beta (5Y Monthly) 1.67
  • PE Ratio (TTM) --
  • EPS (TTM) -3.20
  • Earnings Date Nov 4, 2024 - Nov 8, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 81.21

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.

www.crisprtx.com

407

Full Time Employees

December 31

Fiscal Year Ends

Recent News: CRSP

View More

Performance Overview: CRSP

Trailing total returns as of 9/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

CRSP
28.63%
S&P 500
15.20%

1-Year Return

CRSP
10.53%
S&P 500
23.28%

3-Year Return

CRSP
63.21%
S&P 500
22.29%

5-Year Return

CRSP
1.65%
S&P 500
84.49%

Compare To: CRSP

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: CRSP

View More

Valuation Measures

Annual
As of 9/9/2024
  • Market Cap

    3.82B

  • Enterprise Value

    3.55B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    18.26

  • Price/Book (mrq)

    1.93

  • Enterprise Value/Revenue

    17.74

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -131.44%

  • Return on Assets (ttm)

    -9.77%

  • Return on Equity (ttm)

    -14.00%

  • Revenue (ttm)

    202.23M

  • Net Income Avi to Common (ttm)

    -265.8M

  • Diluted EPS (ttm)

    -3.20

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    2B

  • Total Debt/Equity (mrq)

    11.68%

  • Levered Free Cash Flow (ttm)

    -51.44M

Research Analysis: CRSP

View More

Company Insights: CRSP

Research Reports: CRSP

View More

People Also Watch